RCUS Arcus Biosciences, Inc.: institutional ownership and insider trading
247 funds reported holding $3.99B of Arcus Biosciences, Inc. in their latest 13F filings; in Q2 2026 funds net bought $109M, with 43 new positions and 23 funds selling out; over the last 12 months insiders bought $0 and sold $13.6M on the open market.
Famous investors holding RCUS
- Ken Griffin (Citadel Advisors): $97.5M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $19.6M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $4.10M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $2.97M, 0.0% of the portfolio
Largest institutional holders of RCUS
- GILEAD SCIENCES, INC. (GILD) — $969M
- BlackRock, Inc. (BLK) — $506M
- VANGUARD GROUP INC — $190M
- STATE STREET CORP (STT, STT-PG) — $186M
- WELLINGTON MANAGEMENT GROUP LLP — $182M
- SUVRETTA CAPITAL MANAGEMENT, LLC — $147M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $138M
- FMR LLC — $125M
- VANGUARD CAPITAL MANAGEMENT LLC — $120M
- CITADEL ADVISORS LLC — $97.5M
Recent RCUS insider trades
- Aug 21, 2026: Azoy Alexander sold 2,827 shares ($84.8K)
- Jul 10, 2026: Jaen Juan C. sold 68,569 shares ($2.03M)
- Jun 24, 2026: Jaen Juan C. sold 31,431 shares ($878K)
- Jun 1, 2026: Azoy Alexander sold 2,562 shares ($66.0K)
5%+ owners
- Gilead Sciences, Inc.: 24.7% (Schedule 13D/A, filed Aug 7, 2026)